Quantinuum’s looming IPO tests whether quantum computing is nearing commercial reality. With fault-tolerant breakthroughs, rising revenue, and bold valuations, the company could define the industry’s next decade, if qubits scale fast enough to justify investor faith.

ConocoPhillips’ $22.5 billion acquisition of Marathon Oil boosts scale and free cash flow but prioritizes shareholder returns over innovation. As consolidation deepens in the Permian, U.S. shale grows slower to adapt—shifting power toward OPEC and reshaping global energy dynamics.

Old Glory Bank is wagering its century-old charter on crypto, pursuing a $250 million SPAC merger to fuse FDIC-insured banking with stablecoins, instant on-off ramps, and youth-driven digital demand—while balancing strict regulation against its promise of financial autonomy.

Synopsys’ $35B acquisition of ANSYS is more than a software merger; it’s a bid to control the full lifecycle of digital product design. By combining chip design with simulation and AI-driven optimization, the deal could accelerate innovation worldwide.

SEEQC’s $1B SPAC merger promises speed and capital in a cash-burning quantum race. With anonymous PIPE investors, modest backing, and a sponsor whose deals often underperform, the transaction raises a central question: Is this a breakthrough or a setup for disappointment?

Once dismissed as speculative shortcuts, SPACs have evolved into a legitimate financing tool, especially for early-stage biotech. SL Bio’s $5.7B SPAC merger highlights why firms with long timelines and uncertain revenue may trade dilution and misaligned incentives for speed, certainty, and survival.

Palo Alto Networks’ $8.5B bid for CyberArk signals a shift toward platform dominance in cybersecurity. With strong cash flow, minimal leverage, and rising integration risk, the deal tests whether scale, identity security, and global expansion can deliver $20B in next-generation revenue by 2030.

Crusoe Energy is taking one of the most unconventional paths to the public markets: turning flared natural gas, energy the oil industry treats as waste, into the backbone of AI infrastructure. With a $10 billion valuation, Crusoe is betting that owning both power and compute is key to win AI sector.

By paying nearly six times what it spent on Mandiant, Google is making a decisive bet on cloud security. The acquisition of Wiz promises instant credibility in multi-cloud security, but at a valuation that leaves little room for execution error.

The rush toward AI infrastructure and electrification has turned critical minerals into one of the most crowded trades of 2026. EMAT’s decision to enter public markets through a reverse merger offers speed and exposure, but little of the trust traditionally built through an IPO.

Johnson & Johnson dropped $14.6 billion on a company whose value rests almost entirely on one psychiatric drug. Caplyta may be a blockbuster, or it may be the most expensive overreach in biotech since 2022. This is a high-risk, high-premium gamble at a moment when Big Pharma can’t afford missteps.

Elon Musk just paid $17 billion for spectrum licenses, most experts call worthless, 100 times the going rate. On paper, the deal looks insane. Through Washington’s lens, it’s the smartest move SpaceX has ever made.

The United States has just converted a national security tool into a revenue stream, forcing Nvidia and AMD to surrender 15% of their China chip sales to Washington. What began as a semiconductor export control is now a blueprint for governments to claim stakes in private companies’ earnings.

While everyone piles into AI stocks, the big banks are sandbagging earnings and loading their loan books for the windfall that comes when millions need credit to survive automation.